The content on this site is intended for healthcare professionals only
Prof Jaques van Dongen talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about the immunological monitoring of patients.
Prof van Dongen discusses that of the hot topics is the detection of minimal residual disease (MRD) and how this has become the standard technology.
He also explains that it is key to investigate how leukaemic cells decrease during treatment and how normal B-cells regenerate as this can identify a presence of leukaemic cells that otherwise could not be seen.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
Understanding the remaining unmet needs in a post ASCT NDMM setting
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Guiding transplant decisions in multiple myeloma with MRD
Multiple Myeloma: evolving paradigm - Panel Discussion
Advancements in paediatric Acute lymphoblastic leukemia management
Status of anti BCMA therapy in myeloma
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
